1. Home /
  2. Drug Approvals

Drug Approvals

Ben & Jerry's Wants to Get in on CBD Craze

Ben & Jerry's Wants to Get in on CBD Craze

The company's announcement comes ahead of an FDA's public hearing on the legalization of CBD-infused foods and beverages on Friday.

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

Johnson & Johnson Unveils 5-Year Growth Plan for Pharmaceutical Business

Johnson & Johnson Unveils 5-Year Growth Plan for Pharmaceutical Business

J&J reveals its plans to boost growth within its Janssen pharmaceutical business over the next five years.

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

Shares of ImmunoGen plunge after the U.S. Food and Drug Administration requests additional trials to 'evaluate the safety and efficacy' of one of its cancer-fighting treatments.

Hopeful Signs for These 2 Small Biotech Stocks

Hopeful Signs for These 2 Small Biotech Stocks

Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Catalent to Buy Paragon Bioservices for $1.2 Billion

Catalent to Buy Paragon Bioservices for $1.2 Billion

Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Zogenix Shares Plummet After FDA Rejection of Seizure Treatment

Zogenix Shares Plummet After FDA Rejection of Seizure Treatment

Shares of Zogenix plunge after the FDA rejects an initial marketing application for one of its more promising epilepsy treatment drugs.